Pfizer Inc. and EMD Serono, Merck KHaA’s biopharmaceutical arm in the United States and Canada, recently announced that Bavencio was approved by the Food and Drug Administration for intravenous use. Read More »
Portola Pharmaceuticals Inc. presented data from its pivotal Phase 3 APEX study for the investigational drug betrixaban at a poster session at the American College of Cardiology’s 66th Annual Scientific Session & Expo. Read More »
Sanofi and Regeneron Pharmaceuticals Inc. recently presented Phase 3 clinical trial data and multiple additional analyses from the Praluent (alirocumab) Injection's Odyssey clinical trial program at the American College of Cardiology Scientific Sessions in Washington, D.C. Read More »
Protagonist Therapeutics Inc., announced May 30 that they have formed a worldwide license and collaboration with Janssen Biotech Inc. Read More »
Biohaven Pharmaceutical Holding Company Ltd. has finished its enrollment in the clinical study for trigriluzole for individuals with spinocerebellar ataxia, a rare neurodegenerative disorder. Read More »
Diplomat Pharmacy Inc. is now filling prescriptions for KEVZARA (sarilumab), an FDA-approved medication for the treatment of moderate-to-severe rheumatoid arthritis (RA) in patients who are intolerant to or not receiving enough of a response from other disease modifying antirheumatic drugs. Read More »
Innovus Pharmaceuticals Inc. is signing an exclusive license and distribution agreement for commercialization of Zestra and Zestra Glide with Luminarie Pty Ltd. throughout Australia, New Zealand and the Philippines. Read More »
Sierra Oncology has been granted a selection patent for its Chk1 inhibitor, SRA737 by the U.S. Patent and Trademark Office. Read More »
According to the Technavio’s latest market study, the North American pharmaceutical packaging market is expected to grow through 2021. Read More »
The Pharmaceutical Care Management Association (PCMA) released a statement in support of the Food and Drug Commissioner’s call to publish a list of off-patent drugs that may be vulnerable to price-fixing. Read More »
BioPharma Services Inc. recently passed three Food and Drug Administration inspections without a single Form 483 being issued. Read More »
Direct Relief is working with Pfizer to provide up to a million doses of life-saving Naloxone to community health centers, free clinics, public health departments and other non-profits nationwide in response to the opioid epidemic. Read More »
ScriptSave recently announced that it has partnered with Physicians Mutual to provide discounts on prescription medication to Physicians Mutual customers through its ScriptSave WellRx program. Read More »
Merck has received approval from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for ISENTRESS, a 600 mg. tablet coated in film and paired with other anti-retroviral prescriptions for those who have been diagnosed HIV-1. Read More »
The FDA says it is willing to look into and evaluate a drug that could help treat children who suffer from seizures. Read More »
Hematogenix Laboratory Services, a company that provides integrated pathology services for drug development, recently announced that that Merck & Co. Inc. has included it as one of the national reference laboratories for U.S. Food and Drug Administration (FDA)-approved PD-L1 companion diagnostic assay PD-L1 IHC 22C3 pharmDx for Keytruda. Read More »
Otsuka Pharmaceutical has entered into a licensing agreement that gives it exclusive rights to develop and commercialize Teva Pharmaceutical Industries' migraine prevention drug fremanezumab in Japan. Read More »
Allergan PLC, a global biopharmaceutical company, recently concluded its $2.9 billion acquisition of LifeCell Corp., a business that develops regenerative medicine. Read More »
Janssen Research & Development LLC has identified new partnerships through the company’s Janssen Human Microbiome Institute, a program that develops microbial products through innovation and discovery. Read More »
AM-Pharma B.V. has finished recruiting for its Phase II trial of treatment for individuals with Acute Kidney Injury. Read More »
Alerts Sign-up
